SOURCE: Kalorama Information

Kalorama Information

April 11, 2011 14:44 ET

Pneumococcal Vaccines Lead Growth in Asian Pediatric Markets

NEW YORK, NY--(Marketwire - Apr 11, 2011) - It is estimated that at least two million children die each year from diseases that could have been prevented by already existing vaccines. More than 1.2 million of these deaths, 90% of which occur in the developing world, are a result of pneumococcal diseases, according to the WHO. Pneumococcal conjugate vaccines (PCV) are taking aim at these diseases and healthcare market research publisher Kalorama Information estimates in its new report, "Asian Vaccine Markets," that PCV revenue in Asia grew 18.1% annually since 2006 to reach $442 million in 2010.

"Pneumococcus is a leading cause of serious illness worldwide, and is the most frequent cause of pneumonia, blood infections, sinusitis, and middle ear infections," said Bruce Carlson, publisher of Kalorama Information. "Although all age groups may be affected, the highest rate of pneumococcal disease occurs in young children and the elderly."

In early 2010, the United Nations unveiled an action plan designed to save the lives of 10 million women and children over the next five years. Part of the UN's Millennium Development Goals, the plan calls for increased coverage of three important pediatric vaccines: PCV, rotavirus vaccine, and Haemophilus influenzae type b (Hib) vaccine. It is supported in part by the Bill and Melinda Gates Foundation, which committed $1.5 billion in funding. The initiative is expected to support continued growth of these vaccines.

As noted in Kalorama's report, PCV products include Pfizer's pneumococcal 7-valent conjugate vaccine Prevnar, which is approved for use in children and targets the seven most prevalent serotypes of pneumococcal bacteria (diphtheria CRM197 protein containing 4,6B,9V,14,18C,19F, and 23F). These are among the most resistant to antibiotics and cause 80% of pneumococcal disease in infants, including bloodstream infections and meningitis. The vaccine is 97% protective against invasive pneumococcal disease caused by vaccine serotypes in fully vaccinated children.

"With the continued expansion of Pfizer's Prevnar line, as well as the proliferation of new products from local and foreign manufacturers and distributors, we expect pneumococcal vaccine revenues to continue their double digit annual growth through 2014," said Carlson.

"Asian Vaccine Markets" details and analyzes the Asian market for pediatric and adult vaccines and provides forecasts through 2014. Data covers India, China, Japan, Korea, Indonesia and Rest of Asia. A review of regulatory and IP issues, disease statistics and manufacturer strategies, as well as profiles of top participating companies are included. It is available at:

About Kalorama Information
Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter ( and LinkedIn (

Contact Information